- Home
- DDL vs ALT Comparison
DDL vs ALT Comparison
Compare DDL & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DDL | ALT |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.2M | 573.8M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | DDL | ALT |
|---|---|---|
| Price | $2.06 | $2.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $3.28 | ★ $17.11 |
| AVG Volume (30 Days) | 220.8K | ★ 3.0M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $9.66 | N/A |
| P/E Ratio | $16.08 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $1.65 | $2.56 |
| 52 Week High | $3.41 | $6.44 |
Technical Indicators
Market Signals| Indicator | DDL | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 33.12 | 26.86 |
| Support Level | $1.86 | $2.57 |
| Resistance Level | $2.65 | $3.35 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 0.00 | 4.00 |
Price Performance
Historical ComparisonAbout DDL Dingdong (Cayman) Limited (each two representing three)
Dingdong (Cayman) Ltd are a foremost fresh grocery e-commerce company in mainland China with sustainable growth. It directly provide users and households with fresh groceries, prepared food and other food products through delivering a convenient and excellent shopping experience supported by an extensive self-operated frontline fulfillment grid. The Group operates and manages its business as a single segment. The Group generates substantially all of its revenues from customers in the PRC.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.